中医药抗溃疡性结肠炎复发的临床研究
|
摘要
1研究目的
溃疡性结肠炎(Ulcerative Colitis,UC)又称非特异性溃疡性结肠炎,是一种原因不明的慢性直肠和结肠炎性疾病。因其治愈难度大、病程长,且与结肠癌的发病有关,被世界卫生组织列为现代难治病之一。西医目前无特效治疗药物,且停药后易复发,长期应用副反应多,对顽固性病例疗效不理想。中医药治疗本病有明显的优势,主要表现在降低复发率、改善生活质量及安全性等方面,总体疗效优于西药治疗。
本课题从调节细胞免疫功能、抑制炎症损伤反应、改善微循环状态等方面,深入探讨UC复发的病理机制,并以健脾益气活血、清热化湿解毒的中药复方进行干预,对其预防本病复发的疗效进行客观评价,寻找中医药作用的靶点,进一步明确其抗UC复发的作用机制,确立中药抗UC复发治疗的新思路和方法,为中药抗UC复发寻找理论根据。
2研究方法
本课题以《中药新药临床指导原则》(2002年,试行)中药新药治疗慢性非特异性溃疡性结肠炎的临床研究指导原则为具体参照标准,进行严格的临床研究设计,结合具体临床实际,采用随机、阳性对照的方法,以东直门医院、301医院、306医院的门诊和住院患者为研究对象,依据2000年成都全国炎症性肠病学术研讨会制定的溃疡性结肠炎的诊断标准,选择溃疡性结肠炎慢性复发型活动期的病例87例,治疗组予健脾益气活血、清热化湿解毒的中药汤剂(生炙黄芪各15g炒白术15g茯苓15g赤白芍各10g当归10g三七粉(冲)3g生蒲黄(包)10g炒五灵脂10g黄连10g黄柏10g煨木香10g焦槟榔10g连翘10g公英10g)加减治疗,对照组予柳氮磺胺吡啶(SASP)(4～6g/d)治疗。疗程均为3个月,对部分病例随访6个月,主要观察:(1)疗效观察,包括临床综合疗效,复发率,中医证候疗效,内镜黏膜疗效,临床活动指数、内镜指数的变化,以及生活质量评价的变化。(2)两组治疗前后及随访时的指标变化:外周血CD4+/CD8+/CD3+细胞,血清肿瘤坏死因子-α(TNF-α)、血浆血栓烷素B2(TXB2)、6-酮前列腺素1α(6-Keto-PGF1α)、及TXB2/6-Keto-PGF1α比值。其中TNF-α、TXB2、6-Keto-PGF1α同时检测正常人20例作为正常对照。
3结果
3.1疗效观察结果(1)治疗组临床综合疗效优于对照组(P<0.001);两组完全缓解率(68.18% vs41.86%)和总有效率(95.45% vs 74.42%)比较有统计学意义,治疗组明显优于对照组。(2)两组半年内复发率(治疗组6.67%,对照组50.00%),经统计学检验,有统计学意义(P<0.001),表明中药抗复发作用明显优于柳氮磺胺吡啶。(3)治疗组的中医证候积分远期改善明显优于对照组(P<0.001)。(4)治疗组临床活动指数和内镜指数治疗后较对照组明显下降(均P<0.05),治疗组远期改善亦优于对照组(P<0.001)。(5)治疗组未出现显著的不良反应,而对照组则出现了3例不良反应,1例因不良反应停药。(6)治疗后6个月,治疗组的病理分级与内镜分级均明显低于对照组(P<0.001)。(7)治疗后6个月,治疗组的生活质量改善情况明显优于对照组(P<0.001)。
3. 2免疫学指标变化(1)活动期UC患者外周血CD3+细胞计数、CD8+细胞计数、CD8+细胞百分比均明显高于正常参考值,CD4+/CD8+比值、CD4+百分比明显低于正常参考值。未发现UC患者外周血CD4+细胞绝对计数与正常参考值的差别。UC复发患者CD3+细胞绝对计数、CD8+细胞绝对计数与百分比均显著高于未复发患者,CD4+/CD8+比值、CD4+细胞百分比显著低于未复发患者。治疗后、随访时及二者差值:治疗组外周血CD3+细胞绝对计数、CD8+细胞绝对计数及百分比均显著低于对照组,CD4+/CD8+比值、CD4+细胞百分比显著高于对照组。治疗组随访值与治疗后检测值比较,CD3+细胞绝对计数、CD8+细胞绝对计数及百分比、CD4+/CD8+比值、CD4+细胞百分比无统计学意义(P>0.05);对照组随访值与治疗后检测值比较,CD3+细胞绝对计数、CD4+细胞绝对计数与CD8+细胞绝对计数及百分比有显著差异(P<0.05)。(2)治疗前,UC患者血清TNF-α水平均高于正常值(P<0.001);复发UC患者的血清TNF-α含量明显高于未复发患者。治疗后治疗组血清TNF-α水平均明显低于对照组(P<0.001)。随访时治疗组血清TNF-α水平均明显低于对照组(P<0.001),与治疗后检测值比较治疗组无统计学意义,而对照组差异显著(P<0.001)。(3)治疗前,UC患者血浆TXB2、6-Keto-PGF1α含量,TXB2/6-Keto-PGF1α比值均高于正常值(P<0.001);复发UC患者的血浆TXB2、6-Keto-PGF1α含量,TXB2/6-Keto-PGF1α比值明显高于未复发患者。治疗后治疗组血浆TXB2、6-Keto-PGF1α含量,TXB2/6-Keto-PGF1α比值均明显低于对照组(P<0.001)。随访时治疗组血浆TXB2、6-Keto-PGF1α含量,TXB2/6-Keto-PGF1α比值均明显低于对照组(P<0.001),与治疗后检测值比较治疗组无统计学意义,而对照组差异显著(P<0.001)。
4结论
中医辨证论治治疗溃疡性结肠炎取得了满意的疗效,抗复发效果明显优于柳氮磺胺吡啶。尤其在中医证候学、内镜指数、病理状态方面,显示出中医药在改善溃疡性结肠炎患者生活质量方面具有巨大优势,而且与西药相比无明显毒副作用。可能的作用机制是:①抑制T淋巴细胞亚群的过度增殖,调节亢进的细胞免疫功能;调节T淋巴细胞亚群比例的失衡,改善全身细胞免疫状态;②抑制炎性介质TNF-α的大量表达,阻止炎性细胞的聚集;③改善微循环高凝状态,促进溃疡愈合。④改善患者生活质量,从整体调整患者身心状态,达到治愈UC和减少复发的目的。综上所述,中医药主要通过以上方面,阻断免疫损伤过程,抑制黏膜损伤,促进黏膜愈合,并阻抑愈合后复发。
Background and Objictive
Ulcerative colitis (chronic nonspecific ulcerative colitis) is adisease of digestive tract characterised by chronic inflammation andulceration of colonic mucous membrane. Etiopathogenisis andpathogenesis of the disease is not very clear. Because of its difficultyto cure ,long course of disease and easily to be cancer of colon,it hasbeen known as difficuly disease in the world.At present,there are noeffective western medicine in treating UC. Even these medicines canquickly control the symptoms,the clinical remission rate is high. Andthe disease is easily recurring after drug withdrawal. And side reactionis multi with long-term medication. These medicines are not ideal tointractable cases. Chinese medicine has remarkable preponderance intreating this disease and is obviously superior to western medicine intotal curative effect.
The topic is beginning with the mechanism of immunologic injury,controling the reaction of inflammatory and improving the microcosmiccirculation . We deeply investigate the mechanism of chinese Medicinemethods in treating from the aspects of regulating cellular immunefunction, restraining the reaction of inflammatory injury, promoting therepair of colonic mucous membrane. We deeply analyze the mechanism ofrepressing recur after henosis in order to offer the objective evidenceof reasonably selecting the treating method and medicine. Thus, we canpropose the multiple rings treating theory of UC and the way ofmicrocosmic syndrome differentiation.
Methods
The study was strictly designed under the guidance of GUIDELINE FORNEW DRUGS CLINICAL TRIALS (1997 Edition 3) Guidelines for Treament ofChronic Unspecific Ulcerative Colitis with Chinese Materia Medica. Incombination with actual clinical situation, adopting random positivecontrol method, on the basis of diagnosis criterion established onInflammatory Bowel Disease Seminar at chengdu in 2000, 87 case of chronicrecurrent type in UC active phase was selected from out-patient clinic(OPD) and ward of Dongzhimen Hospital, 301 Hospital, 306 Hospital,treated group received tutor’s proved recipe (trogopterus xanthipesmilne-edwards excrement 10g , typha angustifolia pollen10g, root and redpaeonia root of herbaceous peony 10g apiece,Chinese angelica 6g,driedbetel palm10g, the rhizome of Chinese goldthread 10g, the bark of a corktree 10g , saussurea lappa Clarke root 10g ,forsythia10g, bge root 20g),control group received sulfasalazine (SASP), (4-6g/d). Both treatment course was 3 months, and attend 6 months, main observed index: 1.Therapeutic effect, including clinical general effect, change of TCMsyndrome, therapeutic effect of mucous membrane under endoscope,therapeutic effect of mucous membrane under microscope, the change ofclinical activity index, CAI, endoscopic index. 2. Immue index of bothgroups before and after treatment, CD4+/CD8+/CD3+of peripheral blood,serum Tumornecrosis factor-alpha (TNF-α), plasma TetramethylpyrazineB2(TXB2), 6-keto-prostaglandin F1α(6-Keto-PGF1α). TNF-α,TXB2, 6-Keto-PGF1αwere also detected in 20 normal persons as normal control.
Results
Observation of therapeutic effect1. Clinical general therapeutic effect of treated group is betterthan control group (P<0.001); the total remission percentage of two group(68.18% vs 41.86%), total effective percentage of two group(95.45% vs74.42%), the statistic significant is difference, treated group isobviously better than control group.2.After treatment, the relapse rate in six months of treated groupis obviously lower than that of control group(P<0.001).3. Syndrome scores of treated group was dropped apparently, theforward improvement of treated group is better than control group(P<0.001).4. Clinical activity index (CAI) and endoscopic index of treatedgroup significantly dropped after treatment (P<0.05), the forwardimprovement of control group was better than control group (P<0.001).5. There was no obvious ill-effect on treated group, but three casesof control group had ill-effect, one case stopped receiving treatmentbecause of it.6. After six months of treatment, the pathologic grade and endoscopegrade of the treated group significantly lower than control group(P<0.001).7. After six months of treatment, the qualities of the treated groupwere significiantly better than control group (P<0.001).
The change of immune index1. CD3+ cellular counting, CD8+ cellular counting and percentage ofperipheral blood in active phase of UC patients were significantly higherthan that of normal reference criterion, ratio of CD4+/CD8+, and CD4+ cellular percentage were significantly lowerer than that normalreference criterion, and have relationship with degree of disease andlesion range. There was no difference of CD4+ cellular counting ofperipheral blood between UC patients and healthy people.CD3+ cellular counting ,CD8+ cellular counting and percentage ofperipheral blood in relapse phase of UC patients were significantlyhigher than that of not relapse patients, ratio of CD4+/CD8+, and CD4 +cellular percentage were significantly lowerer than that not relapsepatients.CD3+ cellular counting ,CD8+ cellular counting and percentage ofperipheral blood in treated group were significantly lower than that ofcontrol group, ratio of CD4+/CD8+, and CD4+cellular percentage weresignificantly higher than that of control group after treatment and aftersix months of treatment, CD3+ cellular counting,CD8+ cellular countingand percentage, ratio of CD4 + /CD8 + , CD4 + cellular percentage ofperipheral blood in treated group after six months of treatment weresimilar compared with them after treatment. And CD3+ cellular counting,CD4+cellular counting ,CD8+ cellular counting and percentage in controlgroup after six months of treatment were significantly differentcompared with them after treatment(P<0.05).2. Serum TNF-αconcentration of patients in UC active phase wereremarkblely higher normal value (P<0.001).Serum TNF-αconcentration in relapse phase of UC patients weresignificantly higher than that of not relapse patients.After treatment, serum TNF-αconcentration of treated group weresignificantly lower than that of control group (P<0.001). After sixmonths of treatment, serum TNF-αconcentration of treated group weresignificantly lower than that of control group (P<0.001);The value oftreated group were similar compared with them after treatment; The valueof control group had significantly diffrence compared with them aftertreatment(P<0.001).3.Plasma TXB2、6-Keto-PGF1αconcentration and ratio ofTXB2/6-Keto-PGF1αof patients in UC active phase were remarkblely highernormal value (P<0.001).Plasma TXB2、6-Keto-PGF1αconcentration and ratio ofTXB2/6-Keto-PGF1αin relapse phase of UC patients were significantlyhigher than that of not relapse patients.After treatment, Plasma TXB2、6-Keto-PGF1αconcentration and ratio ofTXB2/6-Keto-PGF1αof treated group were significantly lower than that ofcontrol group (P<0.001). After six months of treatment, Plasma TXB2、6-Keto-PGF1αconcentration and ratio of TXB2/6-Keto-PGF1αof treatedgroup were significantly lower than that of control group (P<0.001);Thevalues of treated group were similar compared with them after treatment;The value of control group had significantly diffrence compared with themafter treatment (P<0.001).
ConclusionsWe have got satisfied therapeutic effect in treating UC by using themethods of determination of treatment based on differentiation ofsyndromes. And the therapeutic effect was obviously better than SASP.Especially in the TCM syndrome, endoscopic index, pathologic index and contra- relapse, showed its superiority in the betterment of livingquality. Compared with western medicine, it had no obvious ill-effect.The following is the contra- relapse mechanism of Chinese medicine: 1.Restraining the excessive generation of T type of lymphocyte subgroup,regulating the accentuated cellular immune function; regulating thedisequilibrium of T type of lymphocyte subgroup, improving cellularimmunity all over the body;2. Restraining the multi expression of TNF-α, preventing the aggregation of inflamed cell;3. Promoting thecirculation of blood so as to promote the repair of injuried mucousmembrane. 4. Improving the qualities of the patients. Therefore, weconsider that chinese medicine has the role of prevent immunologic injury,restraining mucosa injury, promoting repair, so can repress recur afterhenosis .
溃疡性结肠炎(Ulcerative Colitis,UC)又称非特异性溃疡性结肠炎,是一种原因不明的慢性直肠和结肠炎性疾病。因其治愈难度大、病程长,且与结肠癌的发病有关,被世界卫生组织列为现代难治病之一。西医目前无特效治疗药物,且停药后易复发,长期应用副反应多,对顽固性病例疗效不理想。中医药治疗本病有明显的优势,主要表现在降低复发率、改善生活质量及安全性等方面,总体疗效优于西药治疗。
本课题从调节细胞免疫功能、抑制炎症损伤反应、改善微循环状态等方面,深入探讨UC复发的病理机制,并以健脾益气活血、清热化湿解毒的中药复方进行干预,对其预防本病复发的疗效进行客观评价,寻找中医药作用的靶点,进一步明确其抗UC复发的作用机制,确立中药抗UC复发治疗的新思路和方法,为中药抗UC复发寻找理论根据。
2研究方法
本课题以《中药新药临床指导原则》(2002年,试行)中药新药治疗慢性非特异性溃疡性结肠炎的临床研究指导原则为具体参照标准,进行严格的临床研究设计,结合具体临床实际,采用随机、阳性对照的方法,以东直门医院、301医院、306医院的门诊和住院患者为研究对象,依据2000年成都全国炎症性肠病学术研讨会制定的溃疡性结肠炎的诊断标准,选择溃疡性结肠炎慢性复发型活动期的病例87例,治疗组予健脾益气活血、清热化湿解毒的中药汤剂(生炙黄芪各15g炒白术15g茯苓15g赤白芍各10g当归10g三七粉(冲)3g生蒲黄(包)10g炒五灵脂10g黄连10g黄柏10g煨木香10g焦槟榔10g连翘10g公英10g)加减治疗,对照组予柳氮磺胺吡啶(SASP)(4～6g/d)治疗。疗程均为3个月,对部分病例随访6个月,主要观察:(1)疗效观察,包括临床综合疗效,复发率,中医证候疗效,内镜黏膜疗效,临床活动指数、内镜指数的变化,以及生活质量评价的变化。(2)两组治疗前后及随访时的指标变化:外周血CD4+/CD8+/CD3+细胞,血清肿瘤坏死因子-α(TNF-α)、血浆血栓烷素B2(TXB2)、6-酮前列腺素1α(6-Keto-PGF1α)、及TXB2/6-Keto-PGF1α比值。其中TNF-α、TXB2、6-Keto-PGF1α同时检测正常人20例作为正常对照。
3结果
3.1疗效观察结果(1)治疗组临床综合疗效优于对照组(P<0.001);两组完全缓解率(68.18% vs41.86%)和总有效率(95.45% vs 74.42%)比较有统计学意义,治疗组明显优于对照组。(2)两组半年内复发率(治疗组6.67%,对照组50.00%),经统计学检验,有统计学意义(P<0.001),表明中药抗复发作用明显优于柳氮磺胺吡啶。(3)治疗组的中医证候积分远期改善明显优于对照组(P<0.001)。(4)治疗组临床活动指数和内镜指数治疗后较对照组明显下降(均P<0.05),治疗组远期改善亦优于对照组(P<0.001)。(5)治疗组未出现显著的不良反应,而对照组则出现了3例不良反应,1例因不良反应停药。(6)治疗后6个月,治疗组的病理分级与内镜分级均明显低于对照组(P<0.001)。(7)治疗后6个月,治疗组的生活质量改善情况明显优于对照组(P<0.001)。
3. 2免疫学指标变化(1)活动期UC患者外周血CD3+细胞计数、CD8+细胞计数、CD8+细胞百分比均明显高于正常参考值,CD4+/CD8+比值、CD4+百分比明显低于正常参考值。未发现UC患者外周血CD4+细胞绝对计数与正常参考值的差别。UC复发患者CD3+细胞绝对计数、CD8+细胞绝对计数与百分比均显著高于未复发患者,CD4+/CD8+比值、CD4+细胞百分比显著低于未复发患者。治疗后、随访时及二者差值:治疗组外周血CD3+细胞绝对计数、CD8+细胞绝对计数及百分比均显著低于对照组,CD4+/CD8+比值、CD4+细胞百分比显著高于对照组。治疗组随访值与治疗后检测值比较,CD3+细胞绝对计数、CD8+细胞绝对计数及百分比、CD4+/CD8+比值、CD4+细胞百分比无统计学意义(P>0.05);对照组随访值与治疗后检测值比较,CD3+细胞绝对计数、CD4+细胞绝对计数与CD8+细胞绝对计数及百分比有显著差异(P<0.05)。(2)治疗前,UC患者血清TNF-α水平均高于正常值(P<0.001);复发UC患者的血清TNF-α含量明显高于未复发患者。治疗后治疗组血清TNF-α水平均明显低于对照组(P<0.001)。随访时治疗组血清TNF-α水平均明显低于对照组(P<0.001),与治疗后检测值比较治疗组无统计学意义,而对照组差异显著(P<0.001)。(3)治疗前,UC患者血浆TXB2、6-Keto-PGF1α含量,TXB2/6-Keto-PGF1α比值均高于正常值(P<0.001);复发UC患者的血浆TXB2、6-Keto-PGF1α含量,TXB2/6-Keto-PGF1α比值明显高于未复发患者。治疗后治疗组血浆TXB2、6-Keto-PGF1α含量,TXB2/6-Keto-PGF1α比值均明显低于对照组(P<0.001)。随访时治疗组血浆TXB2、6-Keto-PGF1α含量,TXB2/6-Keto-PGF1α比值均明显低于对照组(P<0.001),与治疗后检测值比较治疗组无统计学意义,而对照组差异显著(P<0.001)。
4结论
中医辨证论治治疗溃疡性结肠炎取得了满意的疗效,抗复发效果明显优于柳氮磺胺吡啶。尤其在中医证候学、内镜指数、病理状态方面,显示出中医药在改善溃疡性结肠炎患者生活质量方面具有巨大优势,而且与西药相比无明显毒副作用。可能的作用机制是:①抑制T淋巴细胞亚群的过度增殖,调节亢进的细胞免疫功能;调节T淋巴细胞亚群比例的失衡,改善全身细胞免疫状态;②抑制炎性介质TNF-α的大量表达,阻止炎性细胞的聚集;③改善微循环高凝状态,促进溃疡愈合。④改善患者生活质量,从整体调整患者身心状态,达到治愈UC和减少复发的目的。综上所述,中医药主要通过以上方面,阻断免疫损伤过程,抑制黏膜损伤,促进黏膜愈合,并阻抑愈合后复发。
Background and Objictive
Ulcerative colitis (chronic nonspecific ulcerative colitis) is adisease of digestive tract characterised by chronic inflammation andulceration of colonic mucous membrane. Etiopathogenisis andpathogenesis of the disease is not very clear. Because of its difficultyto cure ,long course of disease and easily to be cancer of colon,it hasbeen known as difficuly disease in the world.At present,there are noeffective western medicine in treating UC. Even these medicines canquickly control the symptoms,the clinical remission rate is high. Andthe disease is easily recurring after drug withdrawal. And side reactionis multi with long-term medication. These medicines are not ideal tointractable cases. Chinese medicine has remarkable preponderance intreating this disease and is obviously superior to western medicine intotal curative effect.
The topic is beginning with the mechanism of immunologic injury,controling the reaction of inflammatory and improving the microcosmiccirculation . We deeply investigate the mechanism of chinese Medicinemethods in treating from the aspects of regulating cellular immunefunction, restraining the reaction of inflammatory injury, promoting therepair of colonic mucous membrane. We deeply analyze the mechanism ofrepressing recur after henosis in order to offer the objective evidenceof reasonably selecting the treating method and medicine. Thus, we canpropose the multiple rings treating theory of UC and the way ofmicrocosmic syndrome differentiation.
Methods
The study was strictly designed under the guidance of GUIDELINE FORNEW DRUGS CLINICAL TRIALS (1997 Edition 3) Guidelines for Treament ofChronic Unspecific Ulcerative Colitis with Chinese Materia Medica. Incombination with actual clinical situation, adopting random positivecontrol method, on the basis of diagnosis criterion established onInflammatory Bowel Disease Seminar at chengdu in 2000, 87 case of chronicrecurrent type in UC active phase was selected from out-patient clinic(OPD) and ward of Dongzhimen Hospital, 301 Hospital, 306 Hospital,treated group received tutor’s proved recipe (trogopterus xanthipesmilne-edwards excrement 10g , typha angustifolia pollen10g, root and redpaeonia root of herbaceous peony 10g apiece,Chinese angelica 6g,driedbetel palm10g, the rhizome of Chinese goldthread 10g, the bark of a corktree 10g , saussurea lappa Clarke root 10g ,forsythia10g, bge root 20g),control group received sulfasalazine (SASP), (4-6g/d). Both treatment course was 3 months, and attend 6 months, main observed index: 1.Therapeutic effect, including clinical general effect, change of TCMsyndrome, therapeutic effect of mucous membrane under endoscope,therapeutic effect of mucous membrane under microscope, the change ofclinical activity index, CAI, endoscopic index. 2. Immue index of bothgroups before and after treatment, CD4+/CD8+/CD3+of peripheral blood,serum Tumornecrosis factor-alpha (TNF-α), plasma TetramethylpyrazineB2(TXB2), 6-keto-prostaglandin F1α(6-Keto-PGF1α). TNF-α,TXB2, 6-Keto-PGF1αwere also detected in 20 normal persons as normal control.
Results
Observation of therapeutic effect1. Clinical general therapeutic effect of treated group is betterthan control group (P<0.001); the total remission percentage of two group(68.18% vs 41.86%), total effective percentage of two group(95.45% vs74.42%), the statistic significant is difference, treated group isobviously better than control group.2.After treatment, the relapse rate in six months of treated groupis obviously lower than that of control group(P<0.001).3. Syndrome scores of treated group was dropped apparently, theforward improvement of treated group is better than control group(P<0.001).4. Clinical activity index (CAI) and endoscopic index of treatedgroup significantly dropped after treatment (P<0.05), the forwardimprovement of control group was better than control group (P<0.001).5. There was no obvious ill-effect on treated group, but three casesof control group had ill-effect, one case stopped receiving treatmentbecause of it.6. After six months of treatment, the pathologic grade and endoscopegrade of the treated group significantly lower than control group(P<0.001).7. After six months of treatment, the qualities of the treated groupwere significiantly better than control group (P<0.001).
The change of immune index1. CD3+ cellular counting, CD8+ cellular counting and percentage ofperipheral blood in active phase of UC patients were significantly higherthan that of normal reference criterion, ratio of CD4+/CD8+, and CD4+ cellular percentage were significantly lowerer than that normalreference criterion, and have relationship with degree of disease andlesion range. There was no difference of CD4+ cellular counting ofperipheral blood between UC patients and healthy people.CD3+ cellular counting ,CD8+ cellular counting and percentage ofperipheral blood in relapse phase of UC patients were significantlyhigher than that of not relapse patients, ratio of CD4+/CD8+, and CD4 +cellular percentage were significantly lowerer than that not relapsepatients.CD3+ cellular counting ,CD8+ cellular counting and percentage ofperipheral blood in treated group were significantly lower than that ofcontrol group, ratio of CD4+/CD8+, and CD4+cellular percentage weresignificantly higher than that of control group after treatment and aftersix months of treatment, CD3+ cellular counting,CD8+ cellular countingand percentage, ratio of CD4 + /CD8 + , CD4 + cellular percentage ofperipheral blood in treated group after six months of treatment weresimilar compared with them after treatment. And CD3+ cellular counting,CD4+cellular counting ,CD8+ cellular counting and percentage in controlgroup after six months of treatment were significantly differentcompared with them after treatment(P<0.05).2. Serum TNF-αconcentration of patients in UC active phase wereremarkblely higher normal value (P<0.001).Serum TNF-αconcentration in relapse phase of UC patients weresignificantly higher than that of not relapse patients.After treatment, serum TNF-αconcentration of treated group weresignificantly lower than that of control group (P<0.001). After sixmonths of treatment, serum TNF-αconcentration of treated group weresignificantly lower than that of control group (P<0.001);The value oftreated group were similar compared with them after treatment; The valueof control group had significantly diffrence compared with them aftertreatment(P<0.001).3.Plasma TXB2、6-Keto-PGF1αconcentration and ratio ofTXB2/6-Keto-PGF1αof patients in UC active phase were remarkblely highernormal value (P<0.001).Plasma TXB2、6-Keto-PGF1αconcentration and ratio ofTXB2/6-Keto-PGF1αin relapse phase of UC patients were significantlyhigher than that of not relapse patients.After treatment, Plasma TXB2、6-Keto-PGF1αconcentration and ratio ofTXB2/6-Keto-PGF1αof treated group were significantly lower than that ofcontrol group (P<0.001). After six months of treatment, Plasma TXB2、6-Keto-PGF1αconcentration and ratio of TXB2/6-Keto-PGF1αof treatedgroup were significantly lower than that of control group (P<0.001);Thevalues of treated group were similar compared with them after treatment;The value of control group had significantly diffrence compared with themafter treatment (P<0.001).
ConclusionsWe have got satisfied therapeutic effect in treating UC by using themethods of determination of treatment based on differentiation ofsyndromes. And the therapeutic effect was obviously better than SASP.Especially in the TCM syndrome, endoscopic index, pathologic index and contra- relapse, showed its superiority in the betterment of livingquality. Compared with western medicine, it had no obvious ill-effect.The following is the contra- relapse mechanism of Chinese medicine: 1.Restraining the excessive generation of T type of lymphocyte subgroup,regulating the accentuated cellular immune function; regulating thedisequilibrium of T type of lymphocyte subgroup, improving cellularimmunity all over the body;2. Restraining the multi expression of TNF-α, preventing the aggregation of inflamed cell;3. Promoting thecirculation of blood so as to promote the repair of injuried mucousmembrane. 4. Improving the qualities of the patients. Therefore, weconsider that chinese medicine has the role of prevent immunologic injury,restraining mucosa injury, promoting repair, so can repress recur afterhenosis .
引文
[1]田海宁. 董建华教授治疗溃疡性结肠炎的经验[J]. 北京中医学院学报,1991,14(1):23-25
[2]危北海. 慢性溃疡性结肠炎的中西医结合防治[J]. 中西医结合杂志,1993,13(4):199-202
[3]李乾构.中医药治疗溃疡性结肠炎的思路[J].北京中医,2004,23(3):149-151
[4]迟莉丽.隗继武教授治疗溃疡性结肠炎的临证应用[J].中医药学刊,2005,23(5):787-789
[5]刘成高,饶群阳.陈光伟治疗慢性溃疡性结肠炎经验[J].实用中医药杂志,2004,20(2):88-89
[6]陈翠仪.从肝论治慢性结肠炎探讨[J].黑龙江中医药,2001,(2):4-6
[7]刘端勇,陈爱民,赵海梅,等.从毒探讨活动期溃疡性结肠炎的发病机制[J].中国中医基础医学杂志,2004,10(4):251-253
[8]马沂,孙跃农.从湿论治慢性非特异性溃疡性结肠炎30 例[J]. 中国民族民间医药杂志,2003, 63:210-211
[9]席作武.活血化瘀法治疗溃疡性结肠炎82例[J].中国中西医结合脾胃杂志,2000,8(3):161-167
[10]孙韦义.中药治疗慢性非特异性溃疡性结肠炎38例临床观察[J].河北中医,1993,15(4):54-56
[11]穆淑清.中西医结合治疗溃疡性结肠炎86例[J].四川中医,1997,15(12):32-35
[12]章阳,叶晨玉.浅谈非特异性溃疡性结肠炎从瘀论治[J].甘肃中医,2005,18(1):4-5
[13]王艳红,郝震,赵聪林.王长洪教授活血化瘀法治疗溃疡性结肠炎经验[J].中医药学刊,2006,24(1):32-34
[14] 罗珊珊,许东云.难治性溃疡性结肠炎的中医辨证论治规律探讨.云南中医中药杂志,2005,26(1):58-60
[15] 张正利,蔡淦,师万西.溃疡性结肠炎中医治疗及理论探讨[J].陕西中医,2001,22(7):405-407
[16] 冯宗清,杨邵波.自拟肠疡宁汤对溃疡性结肠炎结肠镜象的影响[J].湖南中医学院学报,1997,17(3):31
[17] 陈江. 溃疡性结肠炎中医病机演变及证治探讨[J]. 新中医, 2 00 5,3 7(4):34-37
[18]中国中西医结合学会消化系统疾病委员会.第四届全国学术交流会慢性非特异性溃疡性结肠炎中西医结合诊断、辨证和疗性标准(试行方案)[J].中国中西医结合杂志,1994,14:239-240
[19]王立基. 溃愈汤治疗溃疡性结肠炎42例[J].江苏中医药,2006,27(3):18-19
[20]苏佩清,冀绪. 参苓白术散合痛泻要方加减治疗慢性结肠炎77 例[J].实用临床医药杂志,2006,10(2):97-99
[21]丁建华. 除湿活血汤治疗慢性溃疡性结肠炎50 例[J]. 中医研究.2006 ,19(10):37-39
[22]吴邱保. 加味乌梅丸与柳氮磺吡啶治疗慢性溃疡性结肠炎的疗效比较[J].广东医学院学报,2006,24(5):487-489
[23]胡卫海. 清肠益脾汤治疗溃疡性结肠炎40 例[J].江西中医药. 2006, 11(37):28
[24]李瑞东,李佃贵,李晓荟.消溃方治疗溃疡性结肠炎80 例[J].山东中医杂志.2006,25(3):161-163
[25]李铭德. 真人养脏汤化裁方治疗慢性溃疡性结肠炎60 例[J]. 中国民间疗法,2006,14(5):5-8
[26]王小平,李异莲. 自拟马齿苋汤治疗溃疡性结肠炎41 例[J].广西中医药.2006,29 (3):38-40
[27]赵兴无.自拟建脾清肠汤治疗溃疡性结肠炎 72 例[J].国医论坛,2005,20(1):25-27
[28]徐秀全,林凤君.少腹逐瘀汤治疗溃疡性结肠炎 30 例[J].吉林中医药,1996,(4):17-19
[29] 张文荣,王冬娜. 辨证分期治疗非特异性溃疡性结肠炎 116 例观察[J ] .湖南中医杂志,1992 ,8(2) :627-630
[30]吕迎春,宋怀春,王玉新,等.中医辨证治疗慢性溃疡性结肠炎 37 例[J].现代中西医结合杂志,2005,14(8):1047-109
[31]蔡全意,马腾飞,蔡静宜. 辨证治疗溃疡性结肠炎 162 例报道[J]. 甘肃中医,2006,19 (5):17-19
[32]黄文武.中医辨证论治治疗慢性溃疡性结肠炎 56 例[J]. 井冈山学院学报,2006,27(2):122-124
[33]罗珊珊,许东云.难治性溃疡性结肠炎的中医辨证论治规律探讨[J].云南中医中药杂志,2005,26(1):58-59
[34]王新月. 溃疡性结肠炎分期辨治体会[J].江苏中医药,2006,27(1):10-11
[35]张永锋.溃疡性结肠炎证治规律探讨[J].深圳中西医结合杂志,2005,15(2):79-80
[36]朱金萍,曹金梅. 健脾利湿法治疗慢性溃疡性结肠炎124 例临床观察[J].光明中医,2006 ,21(11):21
[37]唐旭东. 活血化瘀法在溃疡性结肠炎治疗中的应用体会[J].江苏中医药,2006,27 (1):13
[38]王垂杰. 清法和温法在溃疡性结肠炎治疗中的应用[J].江苏中医药,2006,27(1):13-14
[39]赵文霞. 溃疡性结肠炎辨治四法[J]. 江苏中医药,2006,27 (1):11-12
[40]林汉平,卢灿辉,池锐忠. 温肾健脾法治疗慢性溃疡性结肠炎42 例.中国中医药科技,2006 ,13 (4):277-279
[41]李磊,石俊旗,宋欣.运用白头翁汤加减灌肠治疗溃疡性结肠炎[J].医药论坛杂志,2006,27(15):100-103
[42]李和平,王进忠. 加味白头翁汤直肠滴注治疗慢性非特异溃疡性结肠炎38例[J]. 河北中医,2006 ,28(5):364-367
[43]孙士然,陈雪清.加味四神汤灌肠治疗慢性非特异性溃疡性结肠炎76例[J].时珍国医国药.2006,17(8):1537-1539
[44]章红.健脾止泻方保留灌肠治疗慢性溃疡性结肠炎38 例疗效观察[J]. 河北中医,2006 ,28 (5):336-338
[45]宋震涛.宽肠饮肠内滴入治疗溃疡性结肠炎38 例报告[J].实用医技杂志,2006, 13(4):571-573
[46]王彩凤,胡娜,来卫东. 运用愈疡安肠方保留灌肠治疗溃疡性结肠炎30 例疗效观察[J]. 河北中医,2006,28(5):345-347
[47]杨玉芬,郝勇.白头翁汤加味治疗溃疡性结肠炎 67 例[J].河南中医,2005,25(4):13-15
[48]吴元祥,陈飞,薛建华,等.黄桂灌肠剂治疗溃疡性结肠炎 47 例[J].中国中西医结合杂志,2005,25(1):83-87
[49]潘洋,于春光,战晶玉.青白灌肠液治疗溃疡性结肠炎 60 例临床观察[J].中国中医药科技,2002,9(4):220-223
[50]齐国有,齐晓霞.葛根芩连汤和白头翁汤四神丸加减治疗慢性结肠炎106 例[J].陕西中医,2006,26(9):1055-1058
[51]范喜军,王建楼,张秀江. 加味连理汤综合治疗慢性溃疡性结肠炎36 例疗效观察[J].四川中医,2006,24(5),49-50
[52] 郑芳忠.桃花汤配合灌肠治疗溃疡性结肠炎62 例[J].国医论坛,2006 , 21(5):8-9
[53]周继鹏,刘少琼,张楚君.乌白汤口服加灌肠治疗溃疡性结肠炎90例[J].四川中医,2005,23(3):38-39
[54]顾维纲.中医治疗慢性非特异性溃疡性结肠炎 26 例[J].湖北中医杂志,2001,23(12):28-29
[55]张金英,刘遇.中药治疗慢性非特异性溃疡性结肠炎178例[J].天津中医学院学报,2000,19(1):24-25
[56] 李虎臣,刘光茂,赵素云.愈疡灵治疗溃疡性结肠炎 96 例[J].中国中西医结合消化杂志,2002,10(1):17-18
[57]黄华丽,王敏英. 中西医结合治疗活动期溃疡性结肠炎30 例[J].陕西中医,2006 ,27 (1):55-56
[58]金丹,胡江鸿. 中西医结合治疗溃疡性结肠炎46 例[J].海南医学,2006,17(1):100-102
[59]郭遂成. 中西医结合治疗溃疡性结肠炎66例疗效观察[J].辽宁中医杂志,2006,33(3):344-345
[60]郭玉波. 中西医结合治疗溃疡性结肠直肠炎100 例临床分析[J].齐鲁医学杂志,2006 ,21(3):248-251
[61]温建珍,迟福,乔秀玲,等.中西医结合治疗慢性溃疡性结肠炎40 例临床观察[J].山东医药,2006 ,46 (13):74-76
[62]郭琳,范亮.中药溃结散联用西药佐治溃疡性结肠炎65例[J].第四军医大学学报.2006,27(8):708-709
[63] 王玉玲.中西医结合治疗溃疡性结肠炎40例疗效观察[J].河北医学,2002,8(2):182-183
[64]华静蕙,李红岩,赵发.大肠水疗配合溃结汤灌肠治疗溃疡性结肠炎34 例[J].河北医科大学学报, 2006,27(3):202-204
[65]石云琼,刘少平. 针灸治疗对溃疡性结肠炎患者细胞因子的影响[J]. 湖北中医杂志, 2006 ,28(2):11-13
[66] 马贵同.中药栓剂防治溃疡性结肠炎的临床试验研究[J].上海中医药杂志,1996,(12):2-4
[67]徐非.特定穴埋线治疗溃疡性结肠炎的临床观察[J].针灸临床杂志,1998,14(6):41-43
[68]朱莹,袁伟建,姚红艳. 穴位埋线对溃疡性结肠炎患者血清 IL-2 受体及 T淋巴细胞亚群的影响[J].中国中西医结合杂志.2003,23 (1):58-60
[69]周语平,杨志军,陈彻,等. 黄芩汤加味对溃疡性结肠炎患者T淋巴细胞亚群功能影响的临床观察[J].甘肃中医, 2004,17(5):32-33
[70]林燕,王新月,田德禄,等. 温下法与温涩法对溃疡性结肠炎外周血T 淋巴细胞亚群的影响[J].中国中西医结合消化杂志,2006,14(2):78-79
[71] 周玲玲,方泰惠,杨舜民,等.复方苦参胶囊对大鼠免疫性结肠炎的保护作用[J]. 陕西中医,2004 ,25 (1):89-91
[72]张芳艳,毛新民,武鸿莉,等. 肝郁脾虚型溃疡性结肠炎大鼠的免疫学研究[J].新疆医科大学学报,2004,27(4):367-368
[73]高亚菲,朱昭明,李旭.慢性溃疡性结肠炎中医“证”与有关免疫生化物质关系的探讨[J]. 西安医科大学学报,1996,(3):356-357
[74]郑舜华,崔儒涛. 补肺益肠方治疗溃疡性结肠炎的实验研究[J]. 上海中医药杂志,2000,(6):10-12
[75]都乐亦.温清并用法对溃疡性结肠炎患者免疫功能的影响[J].江苏中医药,2005,26(5):16-17
[76] 俞亚琴,孙伟正.和解法为主对溃疡性结肠炎患者 TNF - a 、IL - 8 和 sIL- 2R 含量调节作用的研究[J]. 哈尔滨商业大学学报(自然科学版),2002,18(3):249-251
[77]陈维雄,陈金联,陈尼维,等. 川芎嗪对溃疡性结肠炎患者血栓素 B2(TXB2)、6 酮 前列腺素F1a(6- Keto- PGF1α)的影响[J].中国临床医学,2004,11(2):166-167.
[78] 赵复锦,张雄,余小平,等.通因通用法治疗溃疡性结肠炎的临床及实验研究[J].中国中西医结合消化杂志,2005,13(2):85-87
[79]刘万里.肠安胶囊治疗溃疡性结肠炎的实验研究[J].长春中医学院学报,2000,16(4):45-47
[80]江学良,权启镇,王东,等.鱼腥草治疗溃疡性结肠炎大鼠对结肠压力的影响[J]. 世界华人消化杂志,1999 ,7(7) :639
[81] 廉南,草均告,严明清.加味痛泻要方防治溃疡性结肠炎复发的临床研究[J].成都中医药大学学报,2002,25(2):1-2
[82]刘海.舒肠丸治疗溃疡性结肠炎临床研究[J].中华实用中西医杂志,2004,4 (17):1-3
[1] Russet M G. Changes in the incidence of inflammatory bowel disease:what does it mean? [J]. Fur J Intern Med 2000,11:191-196
[2] Jiang XL ,Cui HE An analysis of 10218 ulcerative colitis cases in China[J]. World J Gastroenterol 2002,8:158-161
[3] 徐三荣.溃疡性结肠炎与抗中性粒细胞胞浆自身抗体[J]. 国外医学·生理、病理科学与临床分册,1998,18(2):173 - 174.
[4] 郑家驹.炎症性肠病基础与临床[M].科学出版社.2001,88-89
[5] Mac Donald NJ, Shivers WY,N arum DL, Plum SM, Wingard JN, FuhrmannSR, Liang H, Holland-Linn J, Chen DH, Sim BK. Endostatin bindstropomyosin. A potential modulator of The antitumor activity ofendostatin[J]. B iol Chem 2001,276:25190-25196
[6] Taniguchi M ,Geng X ,Glazier KD, Dasgupta A , LinJ ,Das KM. Cellularimmune response against tropomyosin isoform 5 in ulcerative colitis[J]. Clin lmmunol 2001,101:289-295
[7] Vashishtha A, Fischetti VA. Surface-exposed conserved region of thestreptococcal M protein induces antibodies cross reactive withdenatured forms of myosin[J]. J Immunol1993,150:4693-4701
[8] Farrell RJ, Peppercorn MA. Ulcerative colitis[J]. Lancet 2002,359: 331-340
[9] Cameron EA, Binnie JA, Balan K ,Skerrat SA, Swift A ,Solanki C,Middleton SJ. Oral prednisolone metasulphobenzoate in The treatmentof active ulcerative colitis[J]. Scand Gastroenterol 2003,38:535-539
[10]Schreiber S .Experimental immunomodulatory therapy of inflammatorybowel disease[J]. Nether l J Med 1998,53:24-31
[11]李琪佳,徐敏,官播偿.细胞因子与溃疡性结肠炎中国煤炭工业医学杂志[J]2001,4:411-413
[12]Ashwood P, Harvey R, Verjee T, Wolstencroft R,Thompson RP, Powell JJ.Functional interactions between mucosal IL-1, IL-ra and TGF-beta 1in ulcerative colitis[J]. Inflamm Res 2004,53:53-59
[13]Van Assche G ,Dale I , Noman M ,et al. A pilot study on the use ofthe humanized anti-inteAeukin-2 receptor antibody daclizumab inactive ulcerative Colitis [J].Am J Gastroenterol.2003,98(2):369
[14]Monteleone G, MacDonald TT. Manipulation of cytokines in themanagement of patients with inflammatory bowel disease[J]. Ann Med2000,32:552-560
[15] Tang Y, Zhu JB, Cheng DS, Zhang Y, Cao SQ, Zhou B. Anti-inflammatoryeffects and immunomodulatory effects of interleukin-2[J].Pharmaceutical iotechnology 2004,11:173-177
[16]Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis ofinflammatory bowel disease and colon cancer[J]. Clin Rev AllergyImmunol 2005,28:187-196
[17] Kitamura K, Nakamoto Y, Kaneko S, Mukaida N.Pivotal roles ofinterleukin-6 in transmural inflammation in murine T cell transfercolitis[J]. J Leukoc Biol 2004, 76:1111-1117
[18]邓长生. 溃疡性结肠炎患者白细胞介素-6活性研究[J]. 中华消化杂志2001,21:223-225
[19] Raddatz D, Bockemuhl M, Ramadori G. Quantitative measurement ofcytokine mRNA in inflammatory bowel disease: relation to clinical andendoscopic activity and outcome[J]. Eur J Gastroenterol Hepatol,2005,17:547-557
[20]Tsukada Y, Nakamura T, Iimura M, Iizuka BE, Hayashi N. Cytokineprofile in colonic mucosa of ulcerative colitis correlates withdisease activity and response to granulocy tapheresis[J]. Am JGastroenterol, 2002,97:2820-2828
[21]屠振兴, 李兆申, 许国铭, 龚燕芳, 张文俊. 血清白细胞介素-8与溃疡性结肠炎的关系[J].胃肠病学 2002,7:277-279
[22] Akazawa A ,SakaidaI ,Higaki S ,et al.Increased expression oftumornecrosis factor-alpha messenger RNA in the intestinal mucosa ofinflammatory bowel disease, particularly in patients with disease inthe inactive phase[J].J Gastroenterol ,2002 ,37(5):345.
[23] Komatsu M ,Kobayashi D ,Saito K ,et al.Tumornecrosis factor-alphainserum of patients with inflammatory bowel diseaseas measured by ahigh lysensitive immuno-PCR[J].Cl in Chem ,2001,47(7):1297.
[24]Mittal RD, Bid HK, Ghoshal UC IL-1 receptor antagonist (IL-1Ra) geneolymorphism in patients with inflammatory bowel disease in India[J]. Scand J Gastroenterol 2005; 40: 827-831
[25]Melgar S ,Yeung M M,Bas A ,et al. Over-expression of intedeukin 10inmucosal T cells of patients with active ulcerative colitis[J].Clin Exp Immunol , 2003,134(1):127.
[26] Autschbach F,Braunstein J,Helmke B,Zuna I,Schurmann G,NiemirZI,Wallich R,Otto HF,Merer SC.Insitu expression of interleukin-10 innoninflamed human gut and in inflammatory bowel disease[J].Am JPathol,1998,153:121～130.
[27]Melgar S,Yeung MM,Bas A, Forsberg G,Suhr O,Oberg A,HammarstromS,Danielsson A,Hammarstorm ML.Over-expression of interleukin 10 inmucosal T cells of patients with active ulcerative colitis[J].ClinExp Immunol,2003,134:127～137.
[28]李桂芝,温方红,李廷军, 等. T 淋巴细胞亚群检测与溃疡性结肠炎[J].临床荟萃, 2004, 19(12):711
[29]Bach MA,et al.the use of monoclonal anti-T cell antibodies to studyT cell inbalances in human disease.Clin Exp Immunol,1981,45:449.
[30] Fiocchi C. Inflammatory bowel disease:etiology and pat hogenesis[J].Gast roenterology ,1998,115(1):182-205.
[31] Farrell RJ , Peppercorn MA. Ulcerative colitis[J]. Lancet , 2002 ,359(9303):331-340.
[32] Inoue S , Mat sumoto T , Iida M , et al . Characterization of cytokineexpression in t he rectal mucosa of ulcerative colitis: correlationwit h disease activity[J]. Am J Gastroenterol , 1999 ,94(9):2441-2446.
[33]Vainer B,Nielsen O H. Correlation between circulating solubleICAM-1 and prednisolone-induced amelioration of ulcerative colitis[J].Scand J Gastroenterol,2003,38(3):283-287.
[34]Yoshida Y, Iwai A, Itoh K, Tanaka M, Kato S, Hokari R, Miyaham T ,Koyama H ,Mium S Kobayashi M .Role of inducible nitric oxide synthasein dextran sulphate sodium induced colitis[J]. Aliment PharmacolTher 2000,14(Suppl1):26-32
[35]Grisham MB.Oxidants and free radicals in inflammatory boweldisease[J]. Lancet 1994,344:859-861
[36]Miller M ,Angeles FM, Reuter BK, Bobrowski P ,Sandoval M Dietaryantioxidants protect gut epithelial cells from oxidant-inducedapoptosis[J]. BMC Complement Alfern Med, 2001,1:11
[37]Maciejewski J, Selleri C, Sato T, et al. Br J Haematol, 1995,91:245-252
[38]江学良. 溃疡性结肠炎患者血小板活化的检测[J]. 新消化病杂志,1997,11(5):736
[39] Collins CE, Cihill MR, Newland AC,et al. Platelets circulation inanactivated state in inflammatory bowel disease [ J ] .Gastroenterology, 1994,106(4):840-845
[40]徐萍,吴锡琛. 血小板功能障碍:炎症性肠病研究的一种新动向[M]. 国外医学消化系统疾病分册,1996,16(1):43
[41]Graef V. Baggenstoss AH, Sauer WG, et al. Venous thromblsis occurringin nonspecific ulcerative colitis [ J ] . Arch Intern Med,1996,117(3) :337
[42]张连峰,田曙光,王国新. 溃疡性结肠炎患者血小板功能状态的研究[J].中国实用内科杂志,2000,20(2):98-99
[43] Sedghi S, Fields JZ, Klamut M, et al. Increased production of luminalenhanced chem. Ilum in escence by the inflamed colonic mucosa inpatients with ulcerative colitis[J].Gut, 1993, 34: 1191-1195
[44] IRVIN G P M , MACEYM G, SHA H U et al. Formation of platelet2leukocyteaggregates in inflammatory bowel disease[J ] . Inflamm BowelDis ,2004 ,10:361-363
[45] Kerr 1F, Wyllle AH, Cntrie AR. Apoptosis:a basic blologicalphenomenon with wikl ranging implications in tissue kinctics[J].BrJ C mtar,1972,26:239-245
[46] Iwamoto M, Koji T ,Makiyama K, Kohyski N ,Nakane PK.Apoptosis of cryptEpithelial cell in ulcerative colitis[J]. J Pathol 1996,180:152-159
[47] 严瑾,欧阳钦,陈代云,等.溃疡性结肠炎中Fas/FasL介导的结肠上皮 细 胞凋亡[J].中华消化杂志,2001,21:397-399.
[48] 张文俊,李兆申,许国铭,等.细胞调亡调控蛋白Bcl-2和Bax在溃疡 性 结肠炎表达的研究.中华消化内镜杂志[J],2003,20:262-264
[49] 祝斌,李巧勤,陈垦,等.溃疡性结肠炎患者PMM凋亡与细胞因子水 平 及Bcl-2基因表达的关系[J].中国肛肠病杂志,2004,24:3-6.
[50] 江学良,权启镇,孙自勤,王要军,齐风,王东,张修礼.溃疡性结肠炎患者淋巴细胞凋亡调控蛋白的表达[J].世界华人消化杂志.1999,7:902-905
[51] Neurath M F, Finotto S , FussI ,Boirivant M ,Galls PR, Strober W.Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question[J]. Trends Immunoi2001,22:21-26
[52] Orholm M ,Binder V ,Sorensen TI, Rasmussen LP, Kyvik KO. Concordanceof inflammatory bowel disease among Danish twins: results of anationwide study[J]. Sand J Gastroenterol 2000,35:1075-1081
[53] Orchard TR,Thiyagaraja S ,Welsh KI, Wordsworth BP, Hill Gaston JS,peripheral arthropathies of inflammatory bowel disease[J].Gastroenterology 2000,118:274-278
[54] Einerhand AW, Renes IB, Makkink MK, Van Der Sluts M Buller HA, DekkerJ. Role of mucins in inflammatory bowel disease: important lessonsfrom experimental models[J]. Eur J Gastroenterol Hepatml,2002,14:757-765
[55] CAMPIERI M,GIONCHETTIP. Bacteria as the cause of ulcerative colitis[J].Gut,2001,48:132 - 135
[56] Thomas GA, Rhodes J ,Green JT, Richardson C .Role of smoking ininflammatory bowel disease: implications for therapy[J]. PostgradMed J 2000,76:273-279
[57]Beaugerie L, Massot N, Carbonnel F, Cattan S, Gendre JP, CosnesJ .Impact of cessation of smoking on the course of ulcerative colitis[J]. Am JG astroenterol,2001,96:2113-2116
[58]Richardson C E, Morgan JM, Jasam B , Green JT ,Rhodes J, Williams GT,Lindstrom J, Woonscott S, Peel S, Thomas GA. Effect of smoking andtransdermal nicotine on colonic nicotinic acetylcholine receptors inulcerative colitis[J]. QJ Med 2003,96:57-65
[59]Coolie B, Camilleri M, Bharucha AE, Sandborn WI, Burton D.Colonicmotility in chronic ulcerative proctosigmoiditis and the effects ofnicotine on colonic motility in patients and healthy subjects[J].Aliment Pharmacol Ther 2001,15:653-663
[60]Sher ME, Bank S ,Greenberg R ,Sardinha TC, Weissman S , Bailey B ,Glliland R , Wexner SD. The influence of cigarette smoking on cytokinelevels in patients with inflammatory bowel disease[J]. Inflamm BowelDis 1999,5:73-78
[61]Madretsma S, Woters LM, Van Dijk Jp,Tak CJ,Feyerabend C, Wilson JH,Zijlstra FJ.IN-vivo effect of nicotine on cytokine production byhuman non-adherent ononuclear cells[J]. Eur J Gastroenterol Hepatol1996,8:1017-1020
[62]Theis MK, Boyko EJ. Patient perceptions of causes of inflammatorybowel disease[J]. Ain J G astroenterol 1994,89:1920
[63]Mayer EA. The neurobiology of stress and gastrointestinal disease[J]. Gut 2000,47:861-869
[64]Qiu BS, Valiance BA, Blennerhassett PA, Collins SM. The role of CD4+lymphocytes in the susceptibility of mice to stress inducedreactivation of experimental colitis[J]. Nat Med 1999,5:1178-1182
[65]刘凤芹,楚更五,李子华,等.心理因素与溃疡性结肠炎[J]. 健康心理学杂志,2001,9(4):307.
[66]郑家驹.炎症性肠病[M].上海:上海科学技术文献出版社,1998,16 - 21.
[67]李文波,孙自勤.溃疡性结肠炎治疗药物现状[J].中国临床医学,2004;11(2):144-147
[68]韩英.溃疡性结肠炎的临床维持缓解治疗[J].合理用药,2005,3(4):37
[69] Moum B Ekbom A, Vatn MH, et al. Clinical course during the 1st yearafter diagnosis in ulcerative colitis and Crohn’s disease[J]. Resultsofa large, prospective population-based study insouth easternNorway, 1990～1993. Scand J Gatroenterol,1997,32:1005.
[70] Feutren G, Mihatsch M J. Risk factors for cyclosporine inducednephropathy in patients with auto immune diseases[J]. Nengl JMed ,1992,326:1654.
[71] The Mesalamine Study Group. Anoral preparation of mealamineaslong-term maintenance therapy for ulcerative colitis [ J ] .Arandomized, placebo-controll edtrial. Ann InternMed,1996,124:204.
[72] Bitton A,English.Parameters of clinic ,biology and histology forcalculate the recurring of ulcerative colitis[J].Gastroenterology;2001,120(1):13-20
[73]邓志波. 溃疡性结肠炎外周血 T 淋巴细胞亚群的研究[J]. 河北医学,2004,10(8):675
[74]郑萍,陈胜良,莫剑忠,等.炎症性肠病患者 T 淋巴细胞亚群的改变及临床意义[J].胃肠病学,2000,5(4)220-221[75 朱锋,钱家明,潘国宗,等.IL-1? 和 IL-8mRNA 表达等指标监测溃疡性结肠炎活动的应用[J].中国医学科学院学报;1999;21(5)
[76]周宇,叶文桃,王皓,等.溃疡性结肠炎患者 IL-13 检测和临床价值[J].医生进修杂志(内科版)2004;27(9)
[77]Sander J, FagehorMK, Bakkon JS, et al. p lasma levels of the leuko2cyte L1 p rotein in febrile conditions: relation to actilolgy numberof leukocyte in blood sedimentation reaction and C2reaction protein[J].Scand J Clin Lav Invest, 1984, 22: 357 - 362
[78]Pisa,Italy. Calprotectin is a strong forecasting quota forulcerative colitis[J].Gut;2005,54(3):364-368
[79]刘文斌,吕愈敏,金珠,等. 钙卫蛋白在溃疡性结肠炎患者结肠黏膜及粪便中的表达及临床意义[J]. 北京大学学报( 医学版),2005,37(2):179-182
[1]Prober CS,Chott JR,Saubermaan LJ,et al. Persistent clonal expansionsof peripheral blood CD4 lymphocytea in chronic inflammatory boweldisense[J]. J Immunol,1996,157:3183
[2]中华医学会消化病学分会.对炎症性肠肠病诊断治疗规范的建议[J].中华消化杂志,2001,21(4):236～239
[3]贾黎明,周春立.炎症性肠病的内镜检查[M].见:郑家驹主编.炎症性肠病基础与临床.北京:科学出版社,2001,195
[4]施先艳,邓长生.溃疡性结肠炎[M].见:邓长生,夏冰主编.炎症性肠病.北京:人民卫生出版社,1998,183
[5]Rachmilewitz D. on behalf of an International Study Group. Coatedmesalazine (5-aminosallicylic acid) versus sulphasalazine in thetreatment of active ulcerative colitis: a randomised trial[J]. Br MedJ, 1989,298: 82～86
[6]郑家驹.活动性溃疡性结肠炎的治疗[M].见:郑家驹主编.炎症性肠病基础与临床.北京:科学出版社,2000,254
[7]Bach MA ,Bach JF. The use of monoclonal anti-T cell antibodies to studyT cell imbalance in human diseases[J]. Clin Exp Immunol, 1981, 45:449
[8]CHOUAIB S. Move insight sinto the complex physiology of TNF-a[J] .Immunol Today,1991,12 :141
[9]Carty E,Macey M,Mccartney SA,et al.Ridogtel,a dual thromboxanesynthase inhibitor and receptor antagonist anti-inflammatory profilein inflammatory bowel disease[J].Aliment Pharmacol Ther,2001,14(6):807-810
[10]Volkov VI.Activity of the postanoids system in inflammatory diseaseof the colon[J].Klin Khir,2000 ,10:30-31
[2]危北海. 慢性溃疡性结肠炎的中西医结合防治[J]. 中西医结合杂志,1993,13(4):199-202
[3]李乾构.中医药治疗溃疡性结肠炎的思路[J].北京中医,2004,23(3):149-151
[4]迟莉丽.隗继武教授治疗溃疡性结肠炎的临证应用[J].中医药学刊,2005,23(5):787-789
[5]刘成高,饶群阳.陈光伟治疗慢性溃疡性结肠炎经验[J].实用中医药杂志,2004,20(2):88-89
[6]陈翠仪.从肝论治慢性结肠炎探讨[J].黑龙江中医药,2001,(2):4-6
[7]刘端勇,陈爱民,赵海梅,等.从毒探讨活动期溃疡性结肠炎的发病机制[J].中国中医基础医学杂志,2004,10(4):251-253
[8]马沂,孙跃农.从湿论治慢性非特异性溃疡性结肠炎30 例[J]. 中国民族民间医药杂志,2003, 63:210-211
[9]席作武.活血化瘀法治疗溃疡性结肠炎82例[J].中国中西医结合脾胃杂志,2000,8(3):161-167
[10]孙韦义.中药治疗慢性非特异性溃疡性结肠炎38例临床观察[J].河北中医,1993,15(4):54-56
[11]穆淑清.中西医结合治疗溃疡性结肠炎86例[J].四川中医,1997,15(12):32-35
[12]章阳,叶晨玉.浅谈非特异性溃疡性结肠炎从瘀论治[J].甘肃中医,2005,18(1):4-5
[13]王艳红,郝震,赵聪林.王长洪教授活血化瘀法治疗溃疡性结肠炎经验[J].中医药学刊,2006,24(1):32-34
[14] 罗珊珊,许东云.难治性溃疡性结肠炎的中医辨证论治规律探讨.云南中医中药杂志,2005,26(1):58-60
[15] 张正利,蔡淦,师万西.溃疡性结肠炎中医治疗及理论探讨[J].陕西中医,2001,22(7):405-407
[16] 冯宗清,杨邵波.自拟肠疡宁汤对溃疡性结肠炎结肠镜象的影响[J].湖南中医学院学报,1997,17(3):31
[17] 陈江. 溃疡性结肠炎中医病机演变及证治探讨[J]. 新中医, 2 00 5,3 7(4):34-37
[18]中国中西医结合学会消化系统疾病委员会.第四届全国学术交流会慢性非特异性溃疡性结肠炎中西医结合诊断、辨证和疗性标准(试行方案)[J].中国中西医结合杂志,1994,14:239-240
[19]王立基. 溃愈汤治疗溃疡性结肠炎42例[J].江苏中医药,2006,27(3):18-19
[20]苏佩清,冀绪. 参苓白术散合痛泻要方加减治疗慢性结肠炎77 例[J].实用临床医药杂志,2006,10(2):97-99
[21]丁建华. 除湿活血汤治疗慢性溃疡性结肠炎50 例[J]. 中医研究.2006 ,19(10):37-39
[22]吴邱保. 加味乌梅丸与柳氮磺吡啶治疗慢性溃疡性结肠炎的疗效比较[J].广东医学院学报,2006,24(5):487-489
[23]胡卫海. 清肠益脾汤治疗溃疡性结肠炎40 例[J].江西中医药. 2006, 11(37):28
[24]李瑞东,李佃贵,李晓荟.消溃方治疗溃疡性结肠炎80 例[J].山东中医杂志.2006,25(3):161-163
[25]李铭德. 真人养脏汤化裁方治疗慢性溃疡性结肠炎60 例[J]. 中国民间疗法,2006,14(5):5-8
[26]王小平,李异莲. 自拟马齿苋汤治疗溃疡性结肠炎41 例[J].广西中医药.2006,29 (3):38-40
[27]赵兴无.自拟建脾清肠汤治疗溃疡性结肠炎 72 例[J].国医论坛,2005,20(1):25-27
[28]徐秀全,林凤君.少腹逐瘀汤治疗溃疡性结肠炎 30 例[J].吉林中医药,1996,(4):17-19
[29] 张文荣,王冬娜. 辨证分期治疗非特异性溃疡性结肠炎 116 例观察[J ] .湖南中医杂志,1992 ,8(2) :627-630
[30]吕迎春,宋怀春,王玉新,等.中医辨证治疗慢性溃疡性结肠炎 37 例[J].现代中西医结合杂志,2005,14(8):1047-109
[31]蔡全意,马腾飞,蔡静宜. 辨证治疗溃疡性结肠炎 162 例报道[J]. 甘肃中医,2006,19 (5):17-19
[32]黄文武.中医辨证论治治疗慢性溃疡性结肠炎 56 例[J]. 井冈山学院学报,2006,27(2):122-124
[33]罗珊珊,许东云.难治性溃疡性结肠炎的中医辨证论治规律探讨[J].云南中医中药杂志,2005,26(1):58-59
[34]王新月. 溃疡性结肠炎分期辨治体会[J].江苏中医药,2006,27(1):10-11
[35]张永锋.溃疡性结肠炎证治规律探讨[J].深圳中西医结合杂志,2005,15(2):79-80
[36]朱金萍,曹金梅. 健脾利湿法治疗慢性溃疡性结肠炎124 例临床观察[J].光明中医,2006 ,21(11):21
[37]唐旭东. 活血化瘀法在溃疡性结肠炎治疗中的应用体会[J].江苏中医药,2006,27 (1):13
[38]王垂杰. 清法和温法在溃疡性结肠炎治疗中的应用[J].江苏中医药,2006,27(1):13-14
[39]赵文霞. 溃疡性结肠炎辨治四法[J]. 江苏中医药,2006,27 (1):11-12
[40]林汉平,卢灿辉,池锐忠. 温肾健脾法治疗慢性溃疡性结肠炎42 例.中国中医药科技,2006 ,13 (4):277-279
[41]李磊,石俊旗,宋欣.运用白头翁汤加减灌肠治疗溃疡性结肠炎[J].医药论坛杂志,2006,27(15):100-103
[42]李和平,王进忠. 加味白头翁汤直肠滴注治疗慢性非特异溃疡性结肠炎38例[J]. 河北中医,2006 ,28(5):364-367
[43]孙士然,陈雪清.加味四神汤灌肠治疗慢性非特异性溃疡性结肠炎76例[J].时珍国医国药.2006,17(8):1537-1539
[44]章红.健脾止泻方保留灌肠治疗慢性溃疡性结肠炎38 例疗效观察[J]. 河北中医,2006 ,28 (5):336-338
[45]宋震涛.宽肠饮肠内滴入治疗溃疡性结肠炎38 例报告[J].实用医技杂志,2006, 13(4):571-573
[46]王彩凤,胡娜,来卫东. 运用愈疡安肠方保留灌肠治疗溃疡性结肠炎30 例疗效观察[J]. 河北中医,2006,28(5):345-347
[47]杨玉芬,郝勇.白头翁汤加味治疗溃疡性结肠炎 67 例[J].河南中医,2005,25(4):13-15
[48]吴元祥,陈飞,薛建华,等.黄桂灌肠剂治疗溃疡性结肠炎 47 例[J].中国中西医结合杂志,2005,25(1):83-87
[49]潘洋,于春光,战晶玉.青白灌肠液治疗溃疡性结肠炎 60 例临床观察[J].中国中医药科技,2002,9(4):220-223
[50]齐国有,齐晓霞.葛根芩连汤和白头翁汤四神丸加减治疗慢性结肠炎106 例[J].陕西中医,2006,26(9):1055-1058
[51]范喜军,王建楼,张秀江. 加味连理汤综合治疗慢性溃疡性结肠炎36 例疗效观察[J].四川中医,2006,24(5),49-50
[52] 郑芳忠.桃花汤配合灌肠治疗溃疡性结肠炎62 例[J].国医论坛,2006 , 21(5):8-9
[53]周继鹏,刘少琼,张楚君.乌白汤口服加灌肠治疗溃疡性结肠炎90例[J].四川中医,2005,23(3):38-39
[54]顾维纲.中医治疗慢性非特异性溃疡性结肠炎 26 例[J].湖北中医杂志,2001,23(12):28-29
[55]张金英,刘遇.中药治疗慢性非特异性溃疡性结肠炎178例[J].天津中医学院学报,2000,19(1):24-25
[56] 李虎臣,刘光茂,赵素云.愈疡灵治疗溃疡性结肠炎 96 例[J].中国中西医结合消化杂志,2002,10(1):17-18
[57]黄华丽,王敏英. 中西医结合治疗活动期溃疡性结肠炎30 例[J].陕西中医,2006 ,27 (1):55-56
[58]金丹,胡江鸿. 中西医结合治疗溃疡性结肠炎46 例[J].海南医学,2006,17(1):100-102
[59]郭遂成. 中西医结合治疗溃疡性结肠炎66例疗效观察[J].辽宁中医杂志,2006,33(3):344-345
[60]郭玉波. 中西医结合治疗溃疡性结肠直肠炎100 例临床分析[J].齐鲁医学杂志,2006 ,21(3):248-251
[61]温建珍,迟福,乔秀玲,等.中西医结合治疗慢性溃疡性结肠炎40 例临床观察[J].山东医药,2006 ,46 (13):74-76
[62]郭琳,范亮.中药溃结散联用西药佐治溃疡性结肠炎65例[J].第四军医大学学报.2006,27(8):708-709
[63] 王玉玲.中西医结合治疗溃疡性结肠炎40例疗效观察[J].河北医学,2002,8(2):182-183
[64]华静蕙,李红岩,赵发.大肠水疗配合溃结汤灌肠治疗溃疡性结肠炎34 例[J].河北医科大学学报, 2006,27(3):202-204
[65]石云琼,刘少平. 针灸治疗对溃疡性结肠炎患者细胞因子的影响[J]. 湖北中医杂志, 2006 ,28(2):11-13
[66] 马贵同.中药栓剂防治溃疡性结肠炎的临床试验研究[J].上海中医药杂志,1996,(12):2-4
[67]徐非.特定穴埋线治疗溃疡性结肠炎的临床观察[J].针灸临床杂志,1998,14(6):41-43
[68]朱莹,袁伟建,姚红艳. 穴位埋线对溃疡性结肠炎患者血清 IL-2 受体及 T淋巴细胞亚群的影响[J].中国中西医结合杂志.2003,23 (1):58-60
[69]周语平,杨志军,陈彻,等. 黄芩汤加味对溃疡性结肠炎患者T淋巴细胞亚群功能影响的临床观察[J].甘肃中医, 2004,17(5):32-33
[70]林燕,王新月,田德禄,等. 温下法与温涩法对溃疡性结肠炎外周血T 淋巴细胞亚群的影响[J].中国中西医结合消化杂志,2006,14(2):78-79
[71] 周玲玲,方泰惠,杨舜民,等.复方苦参胶囊对大鼠免疫性结肠炎的保护作用[J]. 陕西中医,2004 ,25 (1):89-91
[72]张芳艳,毛新民,武鸿莉,等. 肝郁脾虚型溃疡性结肠炎大鼠的免疫学研究[J].新疆医科大学学报,2004,27(4):367-368
[73]高亚菲,朱昭明,李旭.慢性溃疡性结肠炎中医“证”与有关免疫生化物质关系的探讨[J]. 西安医科大学学报,1996,(3):356-357
[74]郑舜华,崔儒涛. 补肺益肠方治疗溃疡性结肠炎的实验研究[J]. 上海中医药杂志,2000,(6):10-12
[75]都乐亦.温清并用法对溃疡性结肠炎患者免疫功能的影响[J].江苏中医药,2005,26(5):16-17
[76] 俞亚琴,孙伟正.和解法为主对溃疡性结肠炎患者 TNF - a 、IL - 8 和 sIL- 2R 含量调节作用的研究[J]. 哈尔滨商业大学学报(自然科学版),2002,18(3):249-251
[77]陈维雄,陈金联,陈尼维,等. 川芎嗪对溃疡性结肠炎患者血栓素 B2(TXB2)、6 酮 前列腺素F1a(6- Keto- PGF1α)的影响[J].中国临床医学,2004,11(2):166-167.
[78] 赵复锦,张雄,余小平,等.通因通用法治疗溃疡性结肠炎的临床及实验研究[J].中国中西医结合消化杂志,2005,13(2):85-87
[79]刘万里.肠安胶囊治疗溃疡性结肠炎的实验研究[J].长春中医学院学报,2000,16(4):45-47
[80]江学良,权启镇,王东,等.鱼腥草治疗溃疡性结肠炎大鼠对结肠压力的影响[J]. 世界华人消化杂志,1999 ,7(7) :639
[81] 廉南,草均告,严明清.加味痛泻要方防治溃疡性结肠炎复发的临床研究[J].成都中医药大学学报,2002,25(2):1-2
[82]刘海.舒肠丸治疗溃疡性结肠炎临床研究[J].中华实用中西医杂志,2004,4 (17):1-3
[1] Russet M G. Changes in the incidence of inflammatory bowel disease:what does it mean? [J]. Fur J Intern Med 2000,11:191-196
[2] Jiang XL ,Cui HE An analysis of 10218 ulcerative colitis cases in China[J]. World J Gastroenterol 2002,8:158-161
[3] 徐三荣.溃疡性结肠炎与抗中性粒细胞胞浆自身抗体[J]. 国外医学·生理、病理科学与临床分册,1998,18(2):173 - 174.
[4] 郑家驹.炎症性肠病基础与临床[M].科学出版社.2001,88-89
[5] Mac Donald NJ, Shivers WY,N arum DL, Plum SM, Wingard JN, FuhrmannSR, Liang H, Holland-Linn J, Chen DH, Sim BK. Endostatin bindstropomyosin. A potential modulator of The antitumor activity ofendostatin[J]. B iol Chem 2001,276:25190-25196
[6] Taniguchi M ,Geng X ,Glazier KD, Dasgupta A , LinJ ,Das KM. Cellularimmune response against tropomyosin isoform 5 in ulcerative colitis[J]. Clin lmmunol 2001,101:289-295
[7] Vashishtha A, Fischetti VA. Surface-exposed conserved region of thestreptococcal M protein induces antibodies cross reactive withdenatured forms of myosin[J]. J Immunol1993,150:4693-4701
[8] Farrell RJ, Peppercorn MA. Ulcerative colitis[J]. Lancet 2002,359: 331-340
[9] Cameron EA, Binnie JA, Balan K ,Skerrat SA, Swift A ,Solanki C,Middleton SJ. Oral prednisolone metasulphobenzoate in The treatmentof active ulcerative colitis[J]. Scand Gastroenterol 2003,38:535-539
[10]Schreiber S .Experimental immunomodulatory therapy of inflammatorybowel disease[J]. Nether l J Med 1998,53:24-31
[11]李琪佳,徐敏,官播偿.细胞因子与溃疡性结肠炎中国煤炭工业医学杂志[J]2001,4:411-413
[12]Ashwood P, Harvey R, Verjee T, Wolstencroft R,Thompson RP, Powell JJ.Functional interactions between mucosal IL-1, IL-ra and TGF-beta 1in ulcerative colitis[J]. Inflamm Res 2004,53:53-59
[13]Van Assche G ,Dale I , Noman M ,et al. A pilot study on the use ofthe humanized anti-inteAeukin-2 receptor antibody daclizumab inactive ulcerative Colitis [J].Am J Gastroenterol.2003,98(2):369
[14]Monteleone G, MacDonald TT. Manipulation of cytokines in themanagement of patients with inflammatory bowel disease[J]. Ann Med2000,32:552-560
[15] Tang Y, Zhu JB, Cheng DS, Zhang Y, Cao SQ, Zhou B. Anti-inflammatoryeffects and immunomodulatory effects of interleukin-2[J].Pharmaceutical iotechnology 2004,11:173-177
[16]Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis ofinflammatory bowel disease and colon cancer[J]. Clin Rev AllergyImmunol 2005,28:187-196
[17] Kitamura K, Nakamoto Y, Kaneko S, Mukaida N.Pivotal roles ofinterleukin-6 in transmural inflammation in murine T cell transfercolitis[J]. J Leukoc Biol 2004, 76:1111-1117
[18]邓长生. 溃疡性结肠炎患者白细胞介素-6活性研究[J]. 中华消化杂志2001,21:223-225
[19] Raddatz D, Bockemuhl M, Ramadori G. Quantitative measurement ofcytokine mRNA in inflammatory bowel disease: relation to clinical andendoscopic activity and outcome[J]. Eur J Gastroenterol Hepatol,2005,17:547-557
[20]Tsukada Y, Nakamura T, Iimura M, Iizuka BE, Hayashi N. Cytokineprofile in colonic mucosa of ulcerative colitis correlates withdisease activity and response to granulocy tapheresis[J]. Am JGastroenterol, 2002,97:2820-2828
[21]屠振兴, 李兆申, 许国铭, 龚燕芳, 张文俊. 血清白细胞介素-8与溃疡性结肠炎的关系[J].胃肠病学 2002,7:277-279
[22] Akazawa A ,SakaidaI ,Higaki S ,et al.Increased expression oftumornecrosis factor-alpha messenger RNA in the intestinal mucosa ofinflammatory bowel disease, particularly in patients with disease inthe inactive phase[J].J Gastroenterol ,2002 ,37(5):345.
[23] Komatsu M ,Kobayashi D ,Saito K ,et al.Tumornecrosis factor-alphainserum of patients with inflammatory bowel diseaseas measured by ahigh lysensitive immuno-PCR[J].Cl in Chem ,2001,47(7):1297.
[24]Mittal RD, Bid HK, Ghoshal UC IL-1 receptor antagonist (IL-1Ra) geneolymorphism in patients with inflammatory bowel disease in India[J]. Scand J Gastroenterol 2005; 40: 827-831
[25]Melgar S ,Yeung M M,Bas A ,et al. Over-expression of intedeukin 10inmucosal T cells of patients with active ulcerative colitis[J].Clin Exp Immunol , 2003,134(1):127.
[26] Autschbach F,Braunstein J,Helmke B,Zuna I,Schurmann G,NiemirZI,Wallich R,Otto HF,Merer SC.Insitu expression of interleukin-10 innoninflamed human gut and in inflammatory bowel disease[J].Am JPathol,1998,153:121～130.
[27]Melgar S,Yeung MM,Bas A, Forsberg G,Suhr O,Oberg A,HammarstromS,Danielsson A,Hammarstorm ML.Over-expression of interleukin 10 inmucosal T cells of patients with active ulcerative colitis[J].ClinExp Immunol,2003,134:127～137.
[28]李桂芝,温方红,李廷军, 等. T 淋巴细胞亚群检测与溃疡性结肠炎[J].临床荟萃, 2004, 19(12):711
[29]Bach MA,et al.the use of monoclonal anti-T cell antibodies to studyT cell inbalances in human disease.Clin Exp Immunol,1981,45:449.
[30] Fiocchi C. Inflammatory bowel disease:etiology and pat hogenesis[J].Gast roenterology ,1998,115(1):182-205.
[31] Farrell RJ , Peppercorn MA. Ulcerative colitis[J]. Lancet , 2002 ,359(9303):331-340.
[32] Inoue S , Mat sumoto T , Iida M , et al . Characterization of cytokineexpression in t he rectal mucosa of ulcerative colitis: correlationwit h disease activity[J]. Am J Gastroenterol , 1999 ,94(9):2441-2446.
[33]Vainer B,Nielsen O H. Correlation between circulating solubleICAM-1 and prednisolone-induced amelioration of ulcerative colitis[J].Scand J Gastroenterol,2003,38(3):283-287.
[34]Yoshida Y, Iwai A, Itoh K, Tanaka M, Kato S, Hokari R, Miyaham T ,Koyama H ,Mium S Kobayashi M .Role of inducible nitric oxide synthasein dextran sulphate sodium induced colitis[J]. Aliment PharmacolTher 2000,14(Suppl1):26-32
[35]Grisham MB.Oxidants and free radicals in inflammatory boweldisease[J]. Lancet 1994,344:859-861
[36]Miller M ,Angeles FM, Reuter BK, Bobrowski P ,Sandoval M Dietaryantioxidants protect gut epithelial cells from oxidant-inducedapoptosis[J]. BMC Complement Alfern Med, 2001,1:11
[37]Maciejewski J, Selleri C, Sato T, et al. Br J Haematol, 1995,91:245-252
[38]江学良. 溃疡性结肠炎患者血小板活化的检测[J]. 新消化病杂志,1997,11(5):736
[39] Collins CE, Cihill MR, Newland AC,et al. Platelets circulation inanactivated state in inflammatory bowel disease [ J ] .Gastroenterology, 1994,106(4):840-845
[40]徐萍,吴锡琛. 血小板功能障碍:炎症性肠病研究的一种新动向[M]. 国外医学消化系统疾病分册,1996,16(1):43
[41]Graef V. Baggenstoss AH, Sauer WG, et al. Venous thromblsis occurringin nonspecific ulcerative colitis [ J ] . Arch Intern Med,1996,117(3) :337
[42]张连峰,田曙光,王国新. 溃疡性结肠炎患者血小板功能状态的研究[J].中国实用内科杂志,2000,20(2):98-99
[43] Sedghi S, Fields JZ, Klamut M, et al. Increased production of luminalenhanced chem. Ilum in escence by the inflamed colonic mucosa inpatients with ulcerative colitis[J].Gut, 1993, 34: 1191-1195
[44] IRVIN G P M , MACEYM G, SHA H U et al. Formation of platelet2leukocyteaggregates in inflammatory bowel disease[J ] . Inflamm BowelDis ,2004 ,10:361-363
[45] Kerr 1F, Wyllle AH, Cntrie AR. Apoptosis:a basic blologicalphenomenon with wikl ranging implications in tissue kinctics[J].BrJ C mtar,1972,26:239-245
[46] Iwamoto M, Koji T ,Makiyama K, Kohyski N ,Nakane PK.Apoptosis of cryptEpithelial cell in ulcerative colitis[J]. J Pathol 1996,180:152-159
[47] 严瑾,欧阳钦,陈代云,等.溃疡性结肠炎中Fas/FasL介导的结肠上皮 细 胞凋亡[J].中华消化杂志,2001,21:397-399.
[48] 张文俊,李兆申,许国铭,等.细胞调亡调控蛋白Bcl-2和Bax在溃疡 性 结肠炎表达的研究.中华消化内镜杂志[J],2003,20:262-264
[49] 祝斌,李巧勤,陈垦,等.溃疡性结肠炎患者PMM凋亡与细胞因子水 平 及Bcl-2基因表达的关系[J].中国肛肠病杂志,2004,24:3-6.
[50] 江学良,权启镇,孙自勤,王要军,齐风,王东,张修礼.溃疡性结肠炎患者淋巴细胞凋亡调控蛋白的表达[J].世界华人消化杂志.1999,7:902-905
[51] Neurath M F, Finotto S , FussI ,Boirivant M ,Galls PR, Strober W.Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question[J]. Trends Immunoi2001,22:21-26
[52] Orholm M ,Binder V ,Sorensen TI, Rasmussen LP, Kyvik KO. Concordanceof inflammatory bowel disease among Danish twins: results of anationwide study[J]. Sand J Gastroenterol 2000,35:1075-1081
[53] Orchard TR,Thiyagaraja S ,Welsh KI, Wordsworth BP, Hill Gaston JS,peripheral arthropathies of inflammatory bowel disease[J].Gastroenterology 2000,118:274-278
[54] Einerhand AW, Renes IB, Makkink MK, Van Der Sluts M Buller HA, DekkerJ. Role of mucins in inflammatory bowel disease: important lessonsfrom experimental models[J]. Eur J Gastroenterol Hepatml,2002,14:757-765
[55] CAMPIERI M,GIONCHETTIP. Bacteria as the cause of ulcerative colitis[J].Gut,2001,48:132 - 135
[56] Thomas GA, Rhodes J ,Green JT, Richardson C .Role of smoking ininflammatory bowel disease: implications for therapy[J]. PostgradMed J 2000,76:273-279
[57]Beaugerie L, Massot N, Carbonnel F, Cattan S, Gendre JP, CosnesJ .Impact of cessation of smoking on the course of ulcerative colitis[J]. Am JG astroenterol,2001,96:2113-2116
[58]Richardson C E, Morgan JM, Jasam B , Green JT ,Rhodes J, Williams GT,Lindstrom J, Woonscott S, Peel S, Thomas GA. Effect of smoking andtransdermal nicotine on colonic nicotinic acetylcholine receptors inulcerative colitis[J]. QJ Med 2003,96:57-65
[59]Coolie B, Camilleri M, Bharucha AE, Sandborn WI, Burton D.Colonicmotility in chronic ulcerative proctosigmoiditis and the effects ofnicotine on colonic motility in patients and healthy subjects[J].Aliment Pharmacol Ther 2001,15:653-663
[60]Sher ME, Bank S ,Greenberg R ,Sardinha TC, Weissman S , Bailey B ,Glliland R , Wexner SD. The influence of cigarette smoking on cytokinelevels in patients with inflammatory bowel disease[J]. Inflamm BowelDis 1999,5:73-78
[61]Madretsma S, Woters LM, Van Dijk Jp,Tak CJ,Feyerabend C, Wilson JH,Zijlstra FJ.IN-vivo effect of nicotine on cytokine production byhuman non-adherent ononuclear cells[J]. Eur J Gastroenterol Hepatol1996,8:1017-1020
[62]Theis MK, Boyko EJ. Patient perceptions of causes of inflammatorybowel disease[J]. Ain J G astroenterol 1994,89:1920
[63]Mayer EA. The neurobiology of stress and gastrointestinal disease[J]. Gut 2000,47:861-869
[64]Qiu BS, Valiance BA, Blennerhassett PA, Collins SM. The role of CD4+lymphocytes in the susceptibility of mice to stress inducedreactivation of experimental colitis[J]. Nat Med 1999,5:1178-1182
[65]刘凤芹,楚更五,李子华,等.心理因素与溃疡性结肠炎[J]. 健康心理学杂志,2001,9(4):307.
[66]郑家驹.炎症性肠病[M].上海:上海科学技术文献出版社,1998,16 - 21.
[67]李文波,孙自勤.溃疡性结肠炎治疗药物现状[J].中国临床医学,2004;11(2):144-147
[68]韩英.溃疡性结肠炎的临床维持缓解治疗[J].合理用药,2005,3(4):37
[69] Moum B Ekbom A, Vatn MH, et al. Clinical course during the 1st yearafter diagnosis in ulcerative colitis and Crohn’s disease[J]. Resultsofa large, prospective population-based study insouth easternNorway, 1990～1993. Scand J Gatroenterol,1997,32:1005.
[70] Feutren G, Mihatsch M J. Risk factors for cyclosporine inducednephropathy in patients with auto immune diseases[J]. Nengl JMed ,1992,326:1654.
[71] The Mesalamine Study Group. Anoral preparation of mealamineaslong-term maintenance therapy for ulcerative colitis [ J ] .Arandomized, placebo-controll edtrial. Ann InternMed,1996,124:204.
[72] Bitton A,English.Parameters of clinic ,biology and histology forcalculate the recurring of ulcerative colitis[J].Gastroenterology;2001,120(1):13-20
[73]邓志波. 溃疡性结肠炎外周血 T 淋巴细胞亚群的研究[J]. 河北医学,2004,10(8):675
[74]郑萍,陈胜良,莫剑忠,等.炎症性肠病患者 T 淋巴细胞亚群的改变及临床意义[J].胃肠病学,2000,5(4)220-221[75 朱锋,钱家明,潘国宗,等.IL-1? 和 IL-8mRNA 表达等指标监测溃疡性结肠炎活动的应用[J].中国医学科学院学报;1999;21(5)
[76]周宇,叶文桃,王皓,等.溃疡性结肠炎患者 IL-13 检测和临床价值[J].医生进修杂志(内科版)2004;27(9)
[77]Sander J, FagehorMK, Bakkon JS, et al. p lasma levels of the leuko2cyte L1 p rotein in febrile conditions: relation to actilolgy numberof leukocyte in blood sedimentation reaction and C2reaction protein[J].Scand J Clin Lav Invest, 1984, 22: 357 - 362
[78]Pisa,Italy. Calprotectin is a strong forecasting quota forulcerative colitis[J].Gut;2005,54(3):364-368
[79]刘文斌,吕愈敏,金珠,等. 钙卫蛋白在溃疡性结肠炎患者结肠黏膜及粪便中的表达及临床意义[J]. 北京大学学报( 医学版),2005,37(2):179-182
[1]Prober CS,Chott JR,Saubermaan LJ,et al. Persistent clonal expansionsof peripheral blood CD4 lymphocytea in chronic inflammatory boweldisense[J]. J Immunol,1996,157:3183
[2]中华医学会消化病学分会.对炎症性肠肠病诊断治疗规范的建议[J].中华消化杂志,2001,21(4):236～239
[3]贾黎明,周春立.炎症性肠病的内镜检查[M].见:郑家驹主编.炎症性肠病基础与临床.北京:科学出版社,2001,195
[4]施先艳,邓长生.溃疡性结肠炎[M].见:邓长生,夏冰主编.炎症性肠病.北京:人民卫生出版社,1998,183
[5]Rachmilewitz D. on behalf of an International Study Group. Coatedmesalazine (5-aminosallicylic acid) versus sulphasalazine in thetreatment of active ulcerative colitis: a randomised trial[J]. Br MedJ, 1989,298: 82～86
[6]郑家驹.活动性溃疡性结肠炎的治疗[M].见:郑家驹主编.炎症性肠病基础与临床.北京:科学出版社,2000,254
[7]Bach MA ,Bach JF. The use of monoclonal anti-T cell antibodies to studyT cell imbalance in human diseases[J]. Clin Exp Immunol, 1981, 45:449
[8]CHOUAIB S. Move insight sinto the complex physiology of TNF-a[J] .Immunol Today,1991,12 :141
[9]Carty E,Macey M,Mccartney SA,et al.Ridogtel,a dual thromboxanesynthase inhibitor and receptor antagonist anti-inflammatory profilein inflammatory bowel disease[J].Aliment Pharmacol Ther,2001,14(6):807-810
[10]Volkov VI.Activity of the postanoids system in inflammatory diseaseof the colon[J].Klin Khir,2000 ,10:30-31